Demant stock gains as analysts highlight valuation after strong first-half figures

Demant stock (ISIN DK0010268440) traded at DKK 301.00 on Nasdaq Copenhagen as of September 18, 2026, leaving the Danish hearing-care group’s shares close to their recent highs and slightly below the average analyst target of DKK 302.55 reported this week.

Analysts adjust targets as valuation tightens

According to MarketScreener on September 18, 2026, Oddo lifted its price target for Demant to DKK 275 from a previous DKK 260 and maintained a neutral rating, signaling that the broker now sees the shares modestly overvalued versus fundamentals despite the company’s robust operational performance in 2026.

The same analyst overview from MarketScreener shows a consensus price target of DKK 302.55, only DKK 1.55 above the September 18, 2026 close of DKK 301.00, underlining that the broader analyst community also sees Demant stock as fairly valued near current levels.

With Demant’s last closing price at DKK 301.00 on September 18, 2026 and Oddo’s new target at DKK 275, the broker’s valuation now stands DKK 26.00 below the market price, implying a discount of roughly 8.6 percent versus where the shares are currently trading and reinforcing the cautious neutral stance.

First-half 2026 figures support the share price

According to Demant’s own half-year report for the first six months of 2026, published via its investor-relations pages in August 2026 and summarized by MarketScreener, the group generated revenue of about DKK 11.0 billion in first-half 2026, up roughly 10 percent compared with the same period of 2025, driven mainly by strong demand for hearing aids and diagnostics equipment.

In the same first-half 2026 period, Demant reported operating profit (EBIT) of approximately DKK 2.1 billion, representing an EBIT margin close to 19 percent and an improvement of about 1 percentage point versus the prior-year half, according to the figures compiled by MarketScreener.

Net profit attributable to shareholders for first-half 2026 reached around DKK 1.4 billion, up roughly 12 percent year on year, according to the same compilation by MarketScreener, reflecting both higher volumes and efficiency gains in the company’s hearing-care operations.

Guidance and risk factors frame the outlook

According to the company’s outlook commentary for fiscal 2026, summarized by MarketScreener, Demant continues to project full-year organic revenue growth in the high-single-digit to low-double-digit percent range and aims to maintain an EBIT margin in the high teens, supported by continued product innovation and scale effects.

At the same time, the guidance highlights risks from currency movements and competitive pressure in key markets, with MarketScreener noting that pricing and reimbursement dynamics in hearing care remain an important swing factor for profitability.

For investors, the quantified combination of roughly 10 percent revenue growth and about a 1 percentage point margin improvement in first-half 2026 is a key part of the story that explains why Demant stock is trading within DKK 1.55 of the consensus target, even as individual houses like Oddo place their target DKK 26.00 below the current price.

Stock price and trading context

Demant stock is listed on Nasdaq Copenhagen under the ticker DEMANT, with the reference quote in Danish kroner. As of the most recent completed trading day on Nasdaq Copenhagen, September 18, 2026, the shares closed at DKK 301.00, slightly above the prior close of DKK 299.20 from September 17, 2026, corresponding to a day gain of about 0.6 percent.

Per recent market-data snapshots for Nasdaq Copenhagen, Demant’s share price of DKK 301.00 as of September 18, 2026 stands close to a 52-week high around the low DKK 300s, while the 52-week low lies materially lower in the mid DKK 200s, illustrating how the strong 2026 figures have helped shift the trading range upward over the past year.

More news and analyses on Demant stock